Prostaglandin inhibitors in the treatment of single-system Langerhans cell histiocytosis: pharmacologic rationale and report of two cases.
Therapeutic trials have confirmed the efficacy of a number of approaches to the treatment of single-system Langerhans cell histiocytosis (LCH). Not so well studied, but with some pharmacologic rationale and anecdotal reports of clinical success, are prostaglandin inhibitors. We present here a review of the possible mechanism of action of prostaglandin inhibitors in LCH and 2 cases of single-organ, single-site LCH treated with only prostaglandin inhibitors, both with sustained favorable clinical outcomes.
Goldberg
Scott A
SA
Division of Pediatric Hematology/Oncology, Boston Medical Center, Yawkey Ambulatory Care Center 4S-09, Boston, MA 02118, USA.
O'Connor
Stephen C
SC
Sprinz
Philippa G
PG
D002648:Child; D018572:Disease-Free Survival; D005260:Female; D006646:Histiocytosis, Langerhans-Cell / Q000188:drug therapy* / Q000473:pathology; D006801:Humans; D007223:Infant; D008297:Male; D009288:Naproxen / Q000627:therapeutic use; D011448:Prostaglandin Antagonists / Q000627:therapeutic use*
D011448:Prostaglandin Antagonists; D009288:Naproxen